Xiidra Vs. Restasis for a female patient aged 64 - from FDA reports


Summary

This is a personalized comparison Xiidra, Restasis for a woman aged 64. The study is created by eHealthMe based on reports from FDA.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>



On Apr, 20, 2017

5,724 females aged 64 (±5) who take Xiidra, Restasis are studied.

Number of reports submitted per year:

Xiidra, Restasis for a female patient aged 64.

Information of the patient in this study:

  • Age: 64
  • Gender: female
  • Reason for the study: Dry Eye

Drugs in this study:

  • Restasis (cyclosporine)
  • Xiidra (lifitegrast)

eHealthMe real world results for females aged 64 (±5):

Comparison with the specified adverse outcomes:
Outcome and its % of total reports:

Hairloss:
  • Xiidra: 0.0 %
  • Restasis: 0.82 %

Most common side effects:

Xiidra:
  • Eye Irritation
  • Eye Pain
  • Eye Pruritus
  • Eye Swelling
  • Instillation Site Irritation
  • Instillation Site Pain
  • Instillation Site Reaction
  • Ocular Hyperaemia
  • Taste - Impaired
  • Vision Blurred
Restasis:
  • Blood Creatinine Increased
  • Breathing Difficulty
  • Diarrhea
  • Drug Ineffective
  • Eye Irritation
  • Fatigue
  • Fever
  • Nausea
  • Rashes
  • Weakness

Most common side effects experienced by people in long term use:

Xiidra:
Restasis:
  • Aseptic Necrosis
  • Blood Creatinine Increased
  • Diarrhea
  • Fever
  • High Blood Pressure
  • Kidney Transplant Rejection
  • Pneumonia
  • Renal Failure Acute
  • Renal Impairment
  • Sepsis

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

You can also:

What are the drugs?

What are the symptoms?

Related studies:

Can you answer these questions?

More questions for: Xiidra, Restasis

You may be interested in these reviews

More reviews for: Xiidra, Restasis